MCID: ANL008
MIFTS: 21

Anal Carcinoma in Situ

Categories: Cancer diseases

Aliases & Classifications for Anal Carcinoma in Situ

MalaCards integrated aliases for Anal Carcinoma in Situ:

Name: Anal Carcinoma in Situ 12 15
Carcinoma in Situ of Anal Canal 12 73
Carcinoma in Situ of Anus 12 73
Anal Intraepithelial Neoplasia Grade Iii 12
Anal Carcinoma Stage 0 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9087
ICD9CM 35 230.6

Summaries for Anal Carcinoma in Situ

MalaCards based summary : Anal Carcinoma in Situ, also known as carcinoma in situ of anal canal, is related to cervical cancer and ewing sarcoma. An important gene associated with Anal Carcinoma in Situ is SERPINB3 (Serpin Family B Member 3), and among its related pathways/superpathways is Transcriptional misregulation in cancer. The drugs Fentanyl and Pancreatic Polypeptide have been mentioned in the context of this disorder. Affiliated tissues include skin and liver, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Anal Carcinoma in Situ

Diseases related to Anal Carcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 cervical cancer 9.5 MYC SERPINB3
2 ewing sarcoma 9.0 FUS MYC

Symptoms & Phenotypes for Anal Carcinoma in Situ

GenomeRNAi Phenotypes related to Anal Carcinoma in Situ according to GeneCards Suite gene sharing:

26 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.61 FUS
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 9.61 MYC
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.61 MYC
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.61 MYC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.61 MYC
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.61 FUS
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.61 MYC FUS
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.61 FUS
9 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.44 FUS
10 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.44 FUS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.44 MYC
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.44 FUS
13 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.44 FUS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.44 MYC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.44 MYC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.44 FUS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.44 FUS
18 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.44 FUS
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.44 FUS MYC
20 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.44 FUS

Drugs & Therapeutics for Anal Carcinoma in Situ

Drugs for Anal Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 17)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
3 Analgesics Phase 3
4 Central Nervous System Depressants Phase 3
5 Adjuvants, Anesthesia Phase 3
6 Narcotics Phase 3
7 Analgesics, Opioid Phase 3
8 Anesthetics Phase 3
9 Anesthetics, General Phase 3
10 Anesthetics, Intravenous Phase 3
11 Peripheral Nervous System Agents Phase 3
12 Liver Extracts Phase 3
13 Cola Nutraceutical Phase 3
14
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
15
Cidofovir Approved Phase 2 113852-37-2 60613
16 Anti-Infective Agents Phase 2
17 Antiviral Agents Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus Completed NCT00550589 Phase 2 cidofovir
3 A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand Recruiting NCT03302858 Phase 2

Search NIH Clinical Center for Anal Carcinoma in Situ

Genetic Tests for Anal Carcinoma in Situ

Anatomical Context for Anal Carcinoma in Situ

MalaCards organs/tissues related to Anal Carcinoma in Situ:

41
Skin, Liver

Publications for Anal Carcinoma in Situ

Variations for Anal Carcinoma in Situ

Expression for Anal Carcinoma in Situ

Search GEO for disease gene expression data for Anal Carcinoma in Situ.

Pathways for Anal Carcinoma in Situ

Pathways related to Anal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.89 FUS MYC

GO Terms for Anal Carcinoma in Situ

Biological processes related to Anal Carcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 8.62 MYC SERPINB3

Sources for Anal Carcinoma in Situ

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....